EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CRISPR‐Cas9 and precision editing technologies linking functional genomics to clinical translation in genetic diseases

Zijing Wen iD, Jianming Su

Clinical and Translational Medicine · 2026

DOI: 10.1002/ctm2.70764 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, 2026. Verfasst von Zijing Wen und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Animal Medicine, Hunan Agricultural University, Changsha, China. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing, Genomics, Genetic Diseases, Inborn. Die Arbeit nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CRISPR‐Cas9 and derivative precision‐editing platforms increasingly connect pathogenic variant interpretation with functional genomics and therapeutic development in genetic diseases. This narrative review focuses on a variant‐mechanism‐driven framework for matching editing strategies to mutation structure, functional consequence, disease‐model evidence, delivery feasibility, safety risk, and translational readiness. Main body The review summarizes how monogenic, polygenic, coding, non‐coding, mitochondrial, and complex disease contexts influence the choice of canonical Cas9 editing, base editing, prime editing, Cas variants, CRISPR interference/activation, epigenome editing, and disease‐model systems. It further compares ex vivo and in vivo delivery routes, safety assessment strategies, immunogenicity and genotoxicity concerns, and clinical implementation barriers, including CMC/manufacturing scalability, long‐term follow‐up, affordability, and regulatory oversight. Current evidence supports the clinical maturity of ex vivo hematopoietic editing, whereas most in vivo and precision‐repair approaches remain constrained by delivery, durability, product heterogeneity, and safety uncertainties.

Conclusion

The central conclusion is that future CRISPR‐based interventions should be judged not only by editability, but by whether molecular correction can be translated into durable, safe, manufacturable, and clinically meaningful benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsGene EditingGenomicsGenetic Diseases, InbornTranslational Research, BiomedicalHumansAnimals

Stichwörter der Autor:innen

CRISPR‐Cas9clinical translationgene function researchgenetic diseasespathogenic mutationsprecision editing

Autor:innen und Institutionen

  • College of Animal Medicine, Hunan Agricultural University, Changsha, China.

ORCID-Profile: Zijing Wen

Zitieren

APA

Wen, Z., & Su, J. (2026). CRISPR‐Cas9 and precision editing technologies linking functional genomics to clinical translation in genetic diseases. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70764

Vancouver

Wen Z, Su J. CRISPR‐Cas9 and precision editing technologies linking functional genomics to clinical translation in genetic diseases. Clinical and Translational Medicine. 2026. doi:10.1002/ctm2.70764

BibTeX
@article{Wen2026,
  author = {Wen, Zijing and Su, Jianming},
  title = {CRISPR‐Cas9 and precision editing technologies linking functional genomics to clinical translation in genetic diseases},
  journal = {Clinical and Translational Medicine},
  year = {2026},
  doi = {10.1002/ctm2.70764}
}
Kostenlos starten →